<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 28 Jan 2021 23:53:04 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>第四批国采准入临近尾声，哪些企业竞争力十足？</title><link>https://mp.weixin.qq.com/s/NRdPRT76bpndWOdI20wrJg</link><description></description><content:encoded><![CDATA[第四批国采准入临近尾声，哪些企业竞争力十足？]]></content:encoded><pubDate>Thu, 28 Jan 2021 21:43:42 +0800</pubDate></item><item><title>40个过评药直接挂网，医保品种占屏！</title><link>https://mp.weixin.qq.com/s/4eF6G5y4yVsUNRoxGBeLIw</link><description></description><content:encoded><![CDATA[40个过评药直接挂网，医保品种占屏！]]></content:encoded><pubDate>Thu, 28 Jan 2021 21:43:42 +0800</pubDate></item><item><title>暴降！！这些品种降价53.3%出售</title><link>https://mp.weixin.qq.com/s/CszLAmPj7Pv1UeMCezSvZA</link><description></description><content:encoded><![CDATA[暴降！！这些品种降价53.3%出售]]></content:encoded><pubDate>Thu, 28 Jan 2021 21:43:42 +0800</pubDate></item><item><title>短缺药磋商期满，该如何续约？</title><link>https://mp.weixin.qq.com/s/AGb9njSFKVlDzEdEaNALdg</link><description></description><content:encoded><![CDATA[短缺药磋商期满，该如何续约？]]></content:encoded><pubDate>Thu, 28 Jan 2021 21:43:42 +0800</pubDate></item><item><title>一致性评价新动态，2品种迎多家企业同时过评！</title><link>https://mp.weixin.qq.com/s/RXBiHTsNjG2PG3xvli_bPA</link><description></description><content:encoded><![CDATA[一致性评价新动态，2品种迎多家企业同时过评！]]></content:encoded><pubDate>Wed, 27 Jan 2021 21:33:46 +0800</pubDate></item><item><title>大批医保药下调价格，最高降幅63.1%！</title><link>https://mp.weixin.qq.com/s/nW9sSwzxFdVi7k_001OnLQ</link><description></description><content:encoded><![CDATA[大批医保药下调价格，最高降幅63.1%！]]></content:encoded><pubDate>Wed, 27 Jan 2021 21:33:46 +0800</pubDate></item><item><title>官宣：11个大品种BE指导原则到来</title><link>https://mp.weixin.qq.com/s/WxGfdpu-xQI2Xxwh2hqlqA</link><description></description><content:encoded><![CDATA[官宣：11个大品种BE指导原则到来]]></content:encoded><pubDate>Wed, 27 Jan 2021 21:33:46 +0800</pubDate></item><item><title>《药品注册管理办法》重点疑问解答都在这了</title><link>https://mp.weixin.qq.com/s/Uy-8u7Abo4wsYELdXXG54w</link><description></description><content:encoded><![CDATA[《药品注册管理办法》重点疑问解答都在这了]]></content:encoded><pubDate>Wed, 27 Jan 2021 21:33:46 +0800</pubDate></item><item><title>化药合成界的“珠峰”，专利期过，国内仿制仍空白！</title><link>https://mp.weixin.qq.com/s/IcvQzuRD1Kjs6leFkiAtMg</link><description></description><content:encoded><![CDATA[化药合成界的“珠峰”，专利期过，国内仿制仍空白！]]></content:encoded><pubDate>Tue, 26 Jan 2021 21:40:31 +0800</pubDate></item><item><title>国采乙肝大品种，过评企业再添1家，竞争进入白热化！</title><link>https://mp.weixin.qq.com/s/cXJidZm4mn7KdncJo4ps7Q</link><description></description><content:encoded><![CDATA[国采乙肝大品种，过评企业再添1家，竞争进入白热化！]]></content:encoded><pubDate>Tue, 26 Jan 2021 21:40:31 +0800</pubDate></item><item><title>21个未过评药，暂停采购；涉及恒瑞、天晴、扬子江...</title><link>https://mp.weixin.qq.com/s/XV0BRyHSFN7cmVkOSmR44Q</link><description></description><content:encoded><![CDATA[21个未过评药，暂停采购；涉及恒瑞、天晴、扬子江...]]></content:encoded><pubDate>Tue, 26 Jan 2021 21:40:31 +0800</pubDate></item><item><title>第三十九批参比目录公示；8种审议未通过原因值得关注</title><link>https://mp.weixin.qq.com/s/zooXHy6xOusxxVij_7T7ow</link><description></description><content:encoded><![CDATA[第三十九批参比目录公示；8种审议未通过原因值得关注]]></content:encoded><pubDate>Tue, 26 Jan 2021 21:40:31 +0800</pubDate></item><item><title>国谈助力，一批药品价格“大跌”！</title><link>https://mp.weixin.qq.com/s/9saDTC7rjEFoV0hJYTeVzQ</link><description></description><content:encoded><![CDATA[国谈助力，一批药品价格“大跌”！]]></content:encoded><pubDate>Tue, 26 Jan 2021 21:40:31 +0800</pubDate></item><item><title>（2021.1.25）一致性评价名单，注射剂扎堆过评</title><link>https://mp.weixin.qq.com/s/rJMOUen8-CGIx4xCjFa08Q</link><description></description><content:encoded><![CDATA[（2021.1.25）一致性评价名单，注射剂扎堆过评]]></content:encoded><pubDate>Mon, 25 Jan 2021 21:51:22 +0800</pubDate></item><item><title>这些临床大品种，带量采购后平均降价67.3%！</title><link>https://mp.weixin.qq.com/s/15Rio1VimrgcWk-4oc4nUg</link><description></description><content:encoded><![CDATA[这些临床大品种，带量采购后平均降价67.3%！]]></content:encoded><pubDate>Mon, 25 Jan 2021 21:51:22 +0800</pubDate></item><item><title>第三十六批参比目录发布，59个新增，6个持证增加...</title><link>https://mp.weixin.qq.com/s/SmqRoTRr5zdCQCWfaLdiYQ</link><description></description><content:encoded><![CDATA[第三十六批参比目录发布，59个新增，6个持证增加...]]></content:encoded><pubDate>Mon, 25 Jan 2021 21:51:22 +0800</pubDate></item><item><title>第四批国采，官方细则解读来了</title><link>https://mp.weixin.qq.com/s/Y479vkvpADGLO2jSbTnO0Q</link><description></description><content:encoded><![CDATA[第四批国采，官方细则解读来了]]></content:encoded><pubDate>Mon, 25 Jan 2021 21:51:22 +0800</pubDate></item><item><title>未过评药品，“大限”已到！</title><link>https://mp.weixin.qq.com/s/oXQow_tsA0MQ32b-7Hz17g</link><description></description><content:encoded><![CDATA[未过评药品，“大限”已到！]]></content:encoded><pubDate>Mon, 25 Jan 2021 21:51:22 +0800</pubDate></item><item><title>医保局似曾相识的“招数”，第四批集采得注意了！</title><link>https://mp.weixin.qq.com/s/whWiAtFS6zDS6lLEST_2nw</link><description></description><content:encoded><![CDATA[医保局似曾相识的“招数”，第四批集采得注意了！]]></content:encoded><pubDate>Sat, 23 Jan 2021 21:41:13 +0800</pubDate></item><item><title>百亿BTK抑制剂市场，多少品种在伺机待发？</title><link>https://mp.weixin.qq.com/s/0l9aBe65PFZwLe-zxna-Hw</link><description></description><content:encoded><![CDATA[百亿BTK抑制剂市场，多少品种在伺机待发？]]></content:encoded><pubDate>Fri, 22 Jan 2021 21:50:28 +0800</pubDate></item></channel></rss>